FDA approves Johnson & Johnson’s single-dose Covid vaccine

One dose of vaccine 85% effective, vast study found

Johnson & Johnson’s vaccine was found to offer 85 per cent protection

The Food and Drug Administration has cleared a single-dose Johnson & Johnson  Covid jab for use, adding a third vaccine to the US fight against the pandemic.

Health experts are anxiously awaiting a one-and-done option to help speed vaccinations, as they race against a virus that already has killed more than 510,000 people in the US and is mutating in increasingly worrisome ways.

The FDA said J&J’s vaccine offers strong protection against what matters most: serious illness, hospital admissions and death.

One dose was 85 per cent protective against the most severe Covid-19 illness, in a massive study that spanned three continents — protection that remained strong even in countries such as South Africa, where the variants of most concern are spreading.

“The more vaccines that have high efficacy that we can get into play, the better,” Dr Anthony Fauci, the top US infectious disease expert, said ahead of the FDA’s ruling.

Shipments of a few million doses to be divided among states could begin as early as Monday. By the end of March, J&J has said it expects to deliver 20 million doses to the US, and 100 million by summer.

J&J also is seeking authorisation for emergency use of its vaccine in Europe and from the World Health Organisation. Worldwide, the company aims to produce about 1 billion doses globally by the end of the year. On Thursday, the island nation of Bahrain became the first to clear its use.

Associated Press